Gastric cancer is one
of the leading causes of cancer-related death. Unfortunately, the majority of
gastric cancer patients are diagnosed at advanced stages. For these patients
systemic chemotherapy is the standard treatment. However, prognosis remains
dismal. Therefore, molecular targeting therapy is developed. Among all these
targets, the human epidermal growth factor receptor (HER) family seems to
provide the most promising perspective. Recently, several large phase III trials
on anti-HER agents in gastric cancer have come to conclusions. In this review,
we will discuss available investigations and clinical evidence of anti-HER
agents for the treatment of advanced gastric cancer and provide insight into
future treatment.
This is an open
access article published under the terms of the
Creative
Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the
original work is properly cited.
Cite this article as:
Li J, Cai A, Peng Z, Chen L
(2016). The HER Family: a Vital Target for Advanced Gastric Cancer Therapy.
Acad. J. Pham. Pharmacol. 4(1): 001-019.
